Leaders in Aesthetic Devices Merge: Syneron and Candela
September 9, 2009 – Syneron Medical Ltd. (NASDAQ: ELOS) and Candela Corporation (NASDAQ: CLZR) announced that they have entered into an agreement to combine the companies in an all stock transaction. This strategic combination will create a global leader in medical aesthetic devices. The merger transaction is expected to be completed by year-end 2009.
Syneron and Candela will offer the full range of applications from Syneron’s leading offerings in skin rejuvenation and body sculpting to Candela’s gold standard products from hair removal to vascular and pigmented lesions to tattoo removal to acne reduction.
Candela has been a pioneer in the aesthetic medicine industry for nearly 40 years. Candela manufactures and distributes innovative clinical solutions that enable physicians to treat selected cosmetic and medical conditions using lasers, aesthetic laser systems, and other advanced technologies. Candela established the aesthetic laser market 20 years ago, and currently has an installed base of over 14,000 systems worldwide.
Candela’s product line includes the renowned Vbeam Perfecta and Alex TriVantage laser systems. Equally, Candela’s new QuadraLASE system takes fractional CO2 therapy to the next level.
Syneron manufactures and distributes medical aesthetic devices that are powered by the proprietary, patented elos combined-energy technology of Bi-Polar Radio Frequency and Light.
The elos technology provides the foundation for highly effective, safe and cost-effective systems (eLight, eLaser and eMax) that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin’s appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins.
Other products of Syneron are VelaShape, the first ever FDA cleared device for circumferential reduction and the first class II cleared device for the treatment of cellulite.
Equally, the LipoLite laser lipolysis devices, which are designed to destroy fat cells and coagulate tissue on the body and the face, cost-effectively. It is ideal for areas that are difficult to treat with traditional liposuction, such as under the chin and upper arms.
Transaction Terms
Syneron will maintain its corporate headquarters in Israel and North American office in Irvine, CA. Candela will operate as a wholly-owned subsidiary of Syneron and maintain their offices in Wayland, MA, as well as subsidiary operations in Australia, France, Germany, Italy, Japan, Portugal, Spain and the United Kingdom.
The new company will have proforma annualized revenue totaling over $180 million, based on the quarter ended June 30, 2009, ranking it among the leading medical aesthetic device companies in the industry. The combined company will have a global presence, with approximately 62% of revenue generated from outside the United States, as well as a balanced customer mix between “core physicians” (dermatologists and plastic surgeons) and “non-core physicians” with an approximate split of 55% core and 45% non-core.
Source: www.syneron.com and www.candelalaser.com
